La importancia de la evaluaciónde la adherencia farmacoterapéutica en sujetos con enfermedad cardiovascular
Cargando...
Fecha
2020
Autores
Escobar-Correa, Hannah
Flores-Ramírez, Armando
Urina-Triana, Miguel Alberto
Título de la revista
ISSN de la revista
Título del volumen
Editor
Sociedad Venezolana de Farmacología y de Farmacología Clínica y Terapéutica
Resumen
En Colombia son pocos los programas de vigilancia a la ad- herencia farmacoterapéutica. El objetivo de este estudio fue evaluar la prevalencia y los predictores de no-adherencia en un programa de seguimiento farmacoterapéutico de una co- horte de sujetos con enfermedad cardiovascular y se identi- ficaron los factores asociados con mejoras en la adherencia y evitabilidad.
Métodos: Estudio observacional prospectivo transversal du- rante 9 meses en sujetos con enfermedad cardiovascular de una institución de alta complejidad y se evaluó la adherencia farmacoterapeútica con las metodologías DADER, Escala de New York y criterios Stopp/Start.
Resultados: Se estudiaron 265 sujetos, 72,4% con enfer- medad isquémica, 8% enfermedad valvular, 0,7% insuficien- cia cardiaca y 18,9% enfermedad cardiaca no especificada. Se informaron un total de 484 Problema Relacionado con el Uso de los Medicamentos (PRUM) y 184 Resultado Negativo asociado a la Medicación (RNM). Los PRUM de tipo inte- racción medicamentosa representaron el 56% y el 10% se caracterizó como evitable; los PRUM de tipo administración errónea del medicamento representaron el 20,7% y el 100% se caracterizó como evitable. Los RNM de tipo inseguridad no cuantitativa representaron el 30,6% y el 5% se caracterizó como evitable.
Conclusiones: Se identificaron los factores susceptibles de intervención para promover el uso seguro de medicamentos, así como los asociados con la evitabilidad, la adherencia a la terapia y PRUM. Lo que permitió implementar estrategias para minimizar estos errores durante su tratamiento.
In Colombia there are few surveillance programs for phar- macotherapeutic adherence. The objective of this study was to evaluate the prevalence and predictors of non-adherence in a pharmacotherapeutic follow-up program of a cohort of subjects with cardiovascular disease, and the factors associ- ated with improvements in adherence and avoidability were identified. Methods: A prospective, cross-sectional observational study over a period of 9 months in subjects with cardiovascular dis- ease from a high-complexity institution, and pharmacothera- peutic adherence was evaluated using the DADER method- ologies, the New York Scale and the Stopp / Start criteria. Results: 265 subjects were studied, 72.4% with ischemic disease, 8% valvular disease, 0.7% heart failure and 18.9% unspecified heart disease. A total of 484 Medication Use- Related Problems (PRUM) and 184 Medication-Associated Negative Result (NRM) were reported. Drug interaction type PRUMs represented 56% and 10% were characterized as avoidable; PRUMs of erroneous administration of the drug represented 20.7% and 100% were characterized as avoid- able. Non-quantitative insecurity NRMs represented 30.6% and 5% were characterized as avoidable. Conclusions: Factors susceptible to intervention to promote the safe use of medications, as well as those associated with avoidability, adherence to therapy and PRUM were identified, which allowed the implementation of strategies to minimize these errors during their treatment
In Colombia there are few surveillance programs for phar- macotherapeutic adherence. The objective of this study was to evaluate the prevalence and predictors of non-adherence in a pharmacotherapeutic follow-up program of a cohort of subjects with cardiovascular disease, and the factors associ- ated with improvements in adherence and avoidability were identified. Methods: A prospective, cross-sectional observational study over a period of 9 months in subjects with cardiovascular dis- ease from a high-complexity institution, and pharmacothera- peutic adherence was evaluated using the DADER method- ologies, the New York Scale and the Stopp / Start criteria. Results: 265 subjects were studied, 72.4% with ischemic disease, 8% valvular disease, 0.7% heart failure and 18.9% unspecified heart disease. A total of 484 Medication Use- Related Problems (PRUM) and 184 Medication-Associated Negative Result (NRM) were reported. Drug interaction type PRUMs represented 56% and 10% were characterized as avoidable; PRUMs of erroneous administration of the drug represented 20.7% and 100% were characterized as avoid- able. Non-quantitative insecurity NRMs represented 30.6% and 5% were characterized as avoidable. Conclusions: Factors susceptible to intervention to promote the safe use of medications, as well as those associated with avoidability, adherence to therapy and PRUM were identified, which allowed the implementation of strategies to minimize these errors during their treatment
Descripción
Palabras clave
Farmacovigilancia, Seguimiento farmacote- rapéutico, Adherencia a medicamentos, Problemas relacionados con el uso de medicamentos y resultados negativos de la medicación, Pharmacovigilance, Pharmacotherapeutic follow- up, Medication adherence, Problems related to the use of medications and negative results of the medication